

# Nurse Practitioners

Here is a selection of products on topics that may be of interest to nurse practitioners. These and other CADTH products are open access and available at [cadth.ca](https://cadth.ca). For more information, please contact [requests@cadth.ca](mailto:requests@cadth.ca). The inclusion of reports on particular drugs or other health technologies in this list does not indicate that CADTH endorses these technologies.

## Allergies

- Epinephrine Auto-Injectors for Anaphylaxis: A Review of the Clinical Effectiveness, Cost-Effectiveness, and Guidelines (*Rapid Review*, Apr. 2020)
- Oral Immunotherapy for Food Allergy in Infants and Children: Clinical Effectiveness, Cost-Effectiveness and Guidelines (*Summary of Abstracts*, Oct. 2018)
- Requests and Referrals for Allergy Testing: Guidelines (*Summary of Abstracts*, July 2018)
- Injectable Immunotherapy for Allergy (*Reference List*, Sept. 2021)

## Antipsychotics

- Antipsychotic Drugs or Benzodiazepines for Rapid Tranquilization in Mental Health Facilities or Emergency Department Settings (*Rapid Review*, Aug. 2021)

## Cannabis

- Medical Cannabis (*Research Gaps tool*, Apr. 2020)
- Medicinal and Synthetic Cannabinoids for Pediatric Patients: A Review of Clinical Effectiveness and Guidelines (*Rapid Review*, Oct. 2019)
- The Use of Medical Cannabis With Other Medications: A Review of Safety and Guidelines – An Update (*Rapid Review*, Sept. 2019)
- Medical Cannabis for the Treatment of Chronic Pain: A Review of Clinical Effectiveness and Guidelines (*Rapid Review*, July 2019)

## Contraception

- etonogestrel (Nexplanon) for the Prevention of Pregnancy (*Drug Review Recommendation*, Oct. 2020)
- Ulipristal Versus Levonorgestrel for Emergency Contraception: A Review of Comparative Cost Effectiveness (*Rapid Review*, Feb. 2019)

## Direct Oral Anticoagulants

- Evidence Update on Direct Oral Anticoagulants for Atrial Fibrillation (*Health Technology Review*, May 2021)
- Point-of-Care Testing of International Normalized Ratios for People on Oral Anticoagulants: A Rapid Qualitative Review (*Rapid Review*, Mar. 2021)
- Point-of-Care Testing of International Normalized Ratios for People on Oral Anticoagulants: A Reference List (*Reference List*, Dec. 2020)

## Migraines

- fremanezumab (Ajovy) for Migraine (*Drug Review Recommendation*, Mar. 2021)
- erenumab (Aimovig) for Migraine (*Drug Review Recommendation*, July 2020)
- Small Molecule Calcitonin Gene-Related Peptide Receptor Antagonists for the Acute Treatment of Migraine (*Horizon Scan*, Mar. 2020)
- Non-Invasive Nerve Stimulation Modalities for Migraine Pain: A Review of Clinical Effectiveness and Cost-Effectiveness (*Rapid Review*, Apr. 2020)

CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs and medical devices in our health care system.

CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.